EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gemcitabine‐based conditioning compared to BEAM / BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes

Huimin Liu, Hesong Zou, Dandan Shan, Wei Liu, Wenyang Huang, Weiwei Sui, Shuhui Deng, Tingyu Wang, Rui Lv, Mingwei Fu, Yan Xu, Shuhua Yi und 4 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Huimin Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains an effective treatment for non‐Hodgkin lymphoma (NHL). The limited availability of carmustine has prompted the exploration of novel alternative conditioning regimens. This study aimed to compare the efficacy and safety profile of GBM/GBC (gemcitabine, busulfan, and melphalan or cyclophosphamide) conditioning compared with the standard BEAM/BEAC regimens (carmustine, etoposide, cytarabine, and melphalan or cyclophosphamide) for ASCT in patients with NHL.

Methods

A retrospective analysis was conducted on 231 NHL patients, who underwent ASCT from October 2010 to October 2021 at the Institute of Hematology & Blood Disease Hospital, including both first‐line and salvage settings. This resulted in the inclusion of 112 patients in the GBM/GBC arm and 92 in the BEAM/BEAC arm. Propensity score matching was employed to validate the results.

Results

Disease subtype distribution was similar between the GBM/GBC and BEAM/BEAC groups, with diffuse large B‐cell lymphoma being the most common (58.9% vs. 58.7%), followed by PTCL (17.0% vs. 18.5%) and MCL (14.3% vs. 14.1%). At 3 months post‐ASCT, complete response (CR) rates were comparable (GBM/GBC 93.5% vs. BEAM/BEAC 91.1%; p = 0.607). The 4‐year progression‐free survival (78.4% vs. 82.3%; p = 0.455) and 4‐year overall survival (88.1% vs. 87.7%; p = 0.575) were also similar. Both groups exhibited low non‐relapse mortality at 4 years (GBM/GBC 1.8% vs. BEAM/BEAC 3.5%; p = 0.790) with no transplant‐related mortalities reported. The GBM/GBC cohort demonstrated a higher incidence of grade 3/4 oral mucositis and hepatic toxicity, whereas the BEAM/BEAC group had more frequent cases of bacteremia or sepsis (13 cases vs. 5 in GBM/GBC).

Conclusions

The GBM/GBC regimen is effective and well‐tolerated, offering outcomes that are highly comparable to those in NHL patients conditioned with BEAM/BEAC, as demonstrated in a prognostically matched cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphoma, Non-HodgkinHumansCarmustineGemcitabineMelphalanRetrospective StudiesTransplantation, AutologousCyclophosphamideEtoposideCytarabineAntineoplastic Combined Chemotherapy ProtocolsTransplantation Conditioning

Stichwörter der Autor:innen

autologous stem cell transplantationconditioning regimennon-Hodgkin lymphoma

Substanzen

CarmustineGemcitabineMelphalanCyclophosphamideEtoposideCytarabine

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • Tianjin Institutes of Health Science, Tianjin, China.

ORCID-Profile: Dehui Zou

Förderung

  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Zitieren

APA

Liu, H., Zou, H., Shan, D., Liu, W., Huang, W., Sui, W., Deng, S., Wang, T., Lv, R., Fu, M., Xu, Y., Yi, S., An, G., Zhao, Y., Qiu, L., & Zou, D. (2024). Gemcitabine‐based conditioning compared to BEAM / BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes. Cancer Medicine. https://doi.org/10.1002/cam4.6965

Vancouver

Liu H, Zou H, Shan D, Liu W, Huang W, Sui W, et al. Gemcitabine‐based conditioning compared to BEAM / BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes. Cancer Medicine. 2024. doi:10.1002/cam4.6965

BibTeX
@article{Liu2024,
  author = {Liu, Huimin and Zou, Hesong and Shan, Dandan and Liu, Wei and Huang, Wenyang and Sui, Weiwei and Deng, Shuhui and Wang, Tingyu and Lv, Rui and Fu, Mingwei and Xu, Yan and Yi, Shuhua and An, Gang and Zhao, Yaozhong and Qiu, Lugui and Zou, Dehui},
  title = {Gemcitabine‐based conditioning compared to BEAM / BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6965}
}
Kostenlos starten →